HCM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
HUTCHMED (HCM) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has positive developments in its pipeline, such as the initiation of a Phase III trial for HMPL-760 and a strong net income for 2025, the lack of significant trading signals, neutral hedge fund and insider activity, and recent downward revisions in price targets by analysts suggest a cautious approach. Additionally, the technical indicators and options data do not provide a compelling entry point.
The MACD is positive and expanding, indicating a mild bullish momentum. RSI is neutral at 54.489, and moving averages are converging, suggesting no clear trend. Key support is at 13.791, and resistance is at 14.371. Overall, the technical indicators suggest a lack of strong momentum in either direction.
Initiation of a Phase III trial for HMPL-760 in combination with R-GemOx.
Positive Phase II trial results showing improved response rates and survival.
Strong net income of $456.91 million for 2025.
Recent downward revisions in price targets by analysts.
Discontinuation of clinical trials for tazemetostat, although it was not a significant value driver.
Neutral trading sentiment from hedge funds and insiders.
HUTCHMED reported a net income of $456.91 million for 2025, despite a decline in oncology product revenue. This indicates financial stability, but the decline in a key revenue segment could be a concern.
Analysts maintain a Buy rating but have recently lowered price targets from $25 to $22, then to $21, and most recently to $20. Analysts are cautiously optimistic about the company's future, citing potential growth in oncology/immunology and Fruzaqla markets.
